Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) EPS (Weighted Average and Diluted) (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported EPS (Weighted Average and Diluted) over the past 16 years, most recently at -$0.03 for Q2 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.03 for Q2 2025, up 84.21% from a year ago — trailing twelve months through May 2025 was -$1.28 (down 612.0% YoY), and the annual figure for FY2025 was -$1.27, down 588.46%.
  • EPS (Weighted Average and Diluted) for Q2 2025 was -$0.03 at Lifecore Biomedical, Inc. \De\, up from -$0.47 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for LFCR hit a ceiling of $0.4 in Q1 2024 and a floor of -$1.88 in Q2 2022.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.3 (2021), compared with a mean of -$0.4.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 6166.67% in 2022 and later surged 225.81% in 2023.
  • Lifecore Biomedical, Inc. \De\'s EPS (Weighted Average and Diluted) stood at -$1.31 in 2021, then skyrocketed by 76.34% to -$0.31 in 2022, then surged by 225.81% to $0.39 in 2023, then plummeted by 164.1% to -$0.25 in 2024, then skyrocketed by 88.0% to -$0.03 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.03 (Q2 2025), -$0.47 (Q1 2025), and -$0.25 (Q4 2024) per Business Quant data.